Novartis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. 

CEO
Vasant Narasimhan
CEOVasant Narasimhan
Employees
75,267
Employees75,267
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1996
Founded1996
Employees
75,267
Employees75,267

NVS Key Statistics

Market cap
291.00B
Market cap291.00B
Price-Earnings ratio
21.49
Price-Earnings ratio21.49
Dividend yield
2.15%
Dividend yield2.15%
Average volume
1.87M
Average volume1.87M
High today
$143.01
High today$143.01
Low today
$141.87
Low today$141.87
Open price
$142.80
Open price$142.80
Volume
284.79K
Volume284.79K
52 Week high
$170.46
52 Week high$170.46
52 Week low
$121.57
52 Week low$121.57

NVS News

Reuters 18h
Focus: AI companies run virtual drug trials, aim to improve success of human studies - Reuters

...

Focus: AI companies run virtual drug trials, aim to improve success of human studies - Reuters
Benzinga 19h
FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives

Novartis AG (NYSE:NVS) on Wednesday secured the U.S. Food and Drug Administration (FDA) approval for Rhapsido (remibrutinib) to treat adults with symptomatic de...

FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives
TipRanks 22h
Novartis announces FDA approval of Rhapsido for symptomatic dermographism

Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism inadequately c...

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More NVS News

TipRanks 1d
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?

AI startup BioinvestGPT predicted the failure of Novartis AG’s (NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 result sent the...

TipRanks 3d
Novartis: Buy Rating Reaffirmed, Margin Outlook Strengthens with New Launches; Price Target Unchanged at CHF 150

Bank of America Securities analyst Sachin Jain reiterated a Buy rating on Novartis AG today and set a price target of CHF150.00. Sachin Jain has given his Buy...

The Wall Street Journal 6d
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal

The deal is the latest tie-up between a big Western drugmaker and a Chinese upstart. Arnd Wiegmann / Reuters Novartis NOVN -0.22 %decrease; down pointing trian...

Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
TipRanks 6d
Abogen announces licensing, option agreement with Novartis

Abogen Biosciences, a clinical-stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Nov...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.